Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | GGT1 | P19440 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.36 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002209 | 1.00 | KMT2A (0.42) | KMT2AALOX15BLMPMP22NOD1 | |
| SCHEMBL3652208 | 0.95 | NOD1 (0.44) | KMT2AALOX15BLMPMP22NOD1 | |
| SCHEMBL5965370 | 0.95 | NOD1 (0.44) | KMT2AALOX15BLMPMP22NOD1 | |
| SCHEMBL2250278 | 0.93 | NOD1 (0.46) | KMT2AALOX15BLMPMP22NOD1 | |
| SCHEMBL2254243 | 0.93 | NOD1 (0.46) | KMT2AALOX15BLMPMP22NOD1 | |
| SCHEMBL22042 | 0.89 | KMT2A (0.45) | KMT2AALOX15BLMPMP22NOD1 | |
| SCHEMBL6156358 | 0.89 | KMT2A (0.45) | KMT2AALOX15BLMPMP22NOD1 | |
| SCHEMBL1226472 | 0.89 | KMT2A (0.45) | KMT2AALOX15BLMPMP22NOD1 | |
| SCHEMBL3366485 | 0.88 | NOD1 (0.46) | KMT2AALOX15BLMPMP22NOD1 | |
| SCHEMBL27546911 | 0.88 | NOD1 (0.46) | KMT2AALOX15BLMPMP22NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105440222-B | A kind of polyaminoacid nonionic macromolecules cross-linking agent and preparation method thereof | 宁波大学 | 2018-10-02 | — | — | CN | claimed |
| US-10609922-B2 | Protection of progenitor cells and regulation of their differentiation | PROTEOBIOACTIVES PTY LTD (AU) | 2020-04-07 | — | — | US | disclosed |
| CN-105440222-B | A kind of polyaminoacid nonionic macromolecules cross-linking agent and preparation method thereof | 宁波大学 | 2018-10-02 | — | — | CN | disclosed |
| US-20180206480-A1 | PROTECTION OF PROGENITOR CELLS AND REGULATION OF THEIR DIFFERENTIATION | PROTEOBIOACTIVES PTY LTD (AU) | 2018-07-26 | — | — | US | disclosed |
| CN-103725646-A | Protection of progenitor cells and regulation of their differentiation | PROTEOBIOACTIVES PTY LTD | 2014-04-16 | — | — | CN | disclosed |
| CN-101939417-B | Protection of progenitor cells and modulation of their differentiation | PROTEOBIOACTIVES PTY LTD | 2014-02-05 | — | — | CN | disclosed |
| CN-101939417-A | Protection of progenitor cells and modulation of their differentiation | PROTEOBIOACTIVES PTY LTD | 2011-01-05 | — | — | CN | disclosed |
| CN-1126441-A | Amplification of vitamin B12 absorption System Using polymers | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | disclosed |
| US-5087616-A | Linked by biodegradable polymer to epidermal growth factor | BATTELLE MEMORIAL INSTITUTE (CH) | 1992-02-11 | — | — | US | disclosed |
| EP-0259904-B1 | ADVANCED ANTICANCER THERAPY AND CYTOTOXIC MEDICAMENTS FOR ITS IMPLEMENTATION | IntraCel Corporation (BB) | 1991-06-12 | — | — | EP | disclosed |
| EP-0259904-A1 | Advanced anticancer therapy and cytotoxic medicaments for its implementation | IntraCel Corporation (BB) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10609922-B2 | Protection of progenitor cells and regulation of their differentiation | CD44, MCL1, NES | KMT2A 2675/4885ALOX15 2673/4885BLM 3930/4885 |
| US-20180206480-A1 | PROTECTION OF PROGENITOR CELLS AND REGULATION OF THEIR DIFFERENTIATION | CD44, MCL1, NES | KMT2A 2675/4885ALOX15 2673/4885BLM 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.